Advanced in Interstitial Lung Disease

Dr. Joel A. Wirth

Pulmonary Medicine
100 Foden Road, West Building Suite 103, 
South Portland, ME 
Advanced in Interstitial Lung Disease
100 Foden Road, West Building Suite 103, 
South Portland, ME 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Wirth is a Pulmonary Medicine provider in South Portland, Maine. Dr. Wirth is rated as an Advanced provider by MediFind in the treatment of Interstitial Lung Disease. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Cholesterol Pneumonia, and Lung Metastases.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Interstitial Lung Disease.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in ME
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

100 Foden Road, West Building Suite 103, South Portland, ME 04106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

6 Total Publications

Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial.
Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial.
Journal: Trials
Published: August 10, 2021
Similar Doctors
Distinguished in Interstitial Lung Disease
Dr. Jennifer P. Agren
Pulmonary Medicine
Distinguished in Interstitial Lung Disease
Dr. Jennifer P. Agren
Pulmonary Medicine

Chest Medicine Associates PA

100 Foden Rd, Suite 103, 
South Portland, ME 
 (0.1 miles away)
207-828-1122
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Agren is a Pulmonary Medicine provider in South Portland, Maine. Dr. Agren is rated as a Distinguished provider by MediFind in the treatment of Interstitial Lung Disease. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Cholesterol Pneumonia, and Lung Metastases.

Advanced in Interstitial Lung Disease
Dr. Meagan W. Moore
Pulmonary Medicine | Intensive Care Medicine
Advanced in Interstitial Lung Disease
Dr. Meagan W. Moore
Pulmonary Medicine | Intensive Care Medicine

Mercy Hospital

175 Fore River Pkwy, 
Portland, ME 
 (2.4 miles away)
207-879-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Meagan Moore is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Portland, Maine. Dr. Moore is rated as an Advanced provider by MediFind in the treatment of Interstitial Lung Disease. Her top areas of expertise are Cholesterol Pneumonia, Acute Interstitial Pneumonia, Pulmonary Fibrosis, and Interstitial Lung Disease.

Advanced in Interstitial Lung Disease
Dr. Yasmin Mahal
Pulmonary Medicine
Advanced in Interstitial Lung Disease
Dr. Yasmin Mahal
Pulmonary Medicine

Mainehealth

25 A June St, 
Sanford, ME 
 (25.6 miles away)
Languages Spoken:
English
See accepted insurances

Yasmin Mahal is a Pulmonary Medicine provider in Sanford, Maine. Dr. Mahal is rated as a Distinguished provider by MediFind in the treatment of Interstitial Lung Disease. Her top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Endoscopy, and Pacemaker Implantation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wirth's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile